The use of mesh implants in vaginal prolapse surgery: Position statement and recommendations of the South African Urogynaecology Association

E W Henn, MMed (O&G), FCOG (SA), on behalf of the Executive of the South African Urogynaecology Association

Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of the Free State, Bloemfontein, South Africa

Corresponding author: E W Henn (hennew@ufs.ac.za)

This is the 2014 updated guideline and position statement from the South African Urogynaecology Association on the use of transvaginal mesh for the surgical correction of pelvic organ prolapse.


1. Introduction

Pelvic organ prolapse (POP) is a highly prevalent condition worldwide. It is estimated to affect approximately 50% of parous women. The lifetime risk for surgery for POP or urinary incontinence has in recent times been quoted as 11%. However, new data have shown that this is an underestimation of current trends and that the lifetime risk is currently 20% at the age of 80 years. Although South African data are lacking, local pelvic floor surgeons are seeing an increasing number of women presenting with and requiring surgical correction of prolapse.

The past decade has seen an increase in the use of mesh-based products, with many surgeons electing to use a mesh kit device. The expanding use of mesh kits is due to ease of use, increased surgeon training and the perception that traditional native tissue vaginal pelvic floor repairs for POP have a poor long-term outcome. Aggressive marketing and industry-sponsored training have also played a role in the adoption of these new techniques.

In July 2011 the Food and Drug Administration (FDA) released a document warning surgeons to be selective when using mesh for POP repairs. The FDA concluded that ‘serious complications associated with surgical mesh for transvaginal repair of POP are not rare’ and that ‘it is not clear that transvaginal POP repair with mesh is more effective than traditional non-mesh repair’. One of the recommendations is to ‘choose mesh only after weighing the risks and benefits of surgery with mesh versus all surgical and non-surgical alternatives’. It is significant to note that this warning did not include the use of abdominal mesh for POP surgery (e.g. sacrocolpopexy), or the use of full-length mid-urethral mesh for the treatment of stress urinary incontinence (e.g. tension-free vaginal tape/transobturator sling tape).

In January 2012, the FDA introduced mandatory postmarket surveillance of all mesh implanted in the vagina – so-called ‘522 studies’ – together with the gathering of comparative data between mesh kits and conventional surgery. Since then, some 88 postmarket study orders have been issued to 33 manufacturers of vaginal mesh kits. Given the financial burden of performing such studies, some manufacturers have withdrawn wholly (Johnson & Johnson) or partially (Boston Scientific, CR Bard) from the market, and anecdotally the overall use of vaginally implanted mesh in the USA has fallen by 40 - 60% since the FDA update announcement of July 2011.

The South African Urogynaecology Association (SAUGA) developed this document to serve as a position statement on the use of mesh and mesh-based kits in vaginal POP surgery.

2. Rationale behind the use of transvaginal mesh for POP

Tissue repairs have traditionally been reported as having a poor anatomical outcome. This was in part due to the definition of success based on complete anatomical correction. If the definition is revised to utilise the level of the hymen as the determinant of success, tissue repairs are successful in approximately 75 - 85% of cases. Prolapse recurrence (specifically anterior compartment prolapse) is also noted as a reason for mesh use. These factors were the main initial driving force for the development of transvaginal mesh. Mesh may lead to improved long-term anatomical outcomes, but not necessarily superior functional outcomes.

There are specific complications associated with use of transvaginal mesh. The type and incidence of complications are related to patient selection, procedure selection, surgical technique, and mesh characteristics. The prudent surgeon will therefore select the appropriate technique based on the specific defect, the quality of the tissues, the age of the patient and the surgical history. We should always bear in mind that a large part of surgery remains an art and that we are required to use our training, experience and insight to make the right selection of surgical technique. It is without doubt that certain patients will benefit from the use of mesh, but this decision needs to be a joint one between surgeon and patient after a thorough discussion. The choice is, however, often a personal one without current level 1 evidence guiding this decision.
3. Evaluating the evidence for transvaginal mesh repairs

The past few years have seen a growing body of research into these products; however, the data need to be interpreted with care. Recent years have also seen a number of publications regarding the use of mesh kits for prolapse repairs. Note that many of the mesh kits used previously are also no longer available. There are now sufficient publications to allow systematic reviews and meta-analyses to be published.[6,7]

Unfortunately most case series have significant shortcomings:
- Inclusion criteria are often poorly specified. Various degrees of prolapse are reported grouped together in most series, including primary as well as recurrent prolapse cases.
- Outcomes often include only anatomical description. If functional outcomes are reported, they are limited to dyspareunia, urinary and defecatory dysfunction. Occasionally pain and rarely activities of daily living are reported. Furthermore, if validated questionnaires were used, authors tend to report solely the overall scores, making the analysis of persistent or de novo symptoms difficult.
- Native tissue repair controls are rarely included, and when they are, the surgical techniques tend to differ.
- Most series include single- and multi-site grafted repairs.
- Apart from the use of defined mesh kits, the description of the employed mesh, its properties, how it is tailored, where it is positioned, and what it is attached or sutured to, is typically inadequate.
- The methodology for reporting anatomical outcomes varies.
- Follow-up is usually short, with most series reporting 1 year or less.
- Small case series. The largest report from the French transvaginal mesh group included nearly 800 patients; however, most series include less than 200 patients.
- The learning curve of the surgeons enrolling patients in these studies is typically not described.
- Different inherent properties, including weave, elasticity, total surface area and weight of type 1 polypropylene mesh used in different kits, make complications of case series inaccurate.

4. Patient factors to be considered when using mesh

4.1 Age

It is impossible to guarantee a perfect outcome following any type of POP surgery. Adverse outcomes following mesh repairs, specifically pain and dyspareunia, suggest that caution should be exercised when using mesh in younger sexually active women. A recurrence may be easier to manage than a mesh complication.

4.2 Recurrent prolapse

A woman who has scarred, deficient endopelvic fascia has a greater chance of a recurrence[8] and is therefore a good candidate for a mesh procedure.[9] However, these patients should be warned that there is an increase in the incidence of surgical complications such as bladder and rectal injury, and further recurrence. Realistic expectations should be raised in the preoperative counselling.

4.3 Site of prolapse

There are clear differences in the incidence, severity and recurrence rates of prolapse in the anterior, apical and posterior compartments. Anterior prolapse is more prevalent and more prone to failure after repair.[10,11] Large cystoceles invariably have an apical support defect which needs to be borne in mind when deciding on the surgical approach and technique.[11]

4.4 Collagen deficiency

Currently we have limited objective or laboratory criteria to assess women adequately for collagen deficiency. However, in a patient who has a clear history of joint hypermobility, laxity or a history of hernioses, due consideration should be given to the use of a mesh product.

4.5 Chronic and repetitive increases in intra-abdominal pressure

This group includes women with chronic cough, chronic obstructive pulmonary disease or chronic constipation, and who encounter occupational heavy lifting. These may be indications for the use of mesh-based products, but underlying conditions should be optimised prior to embarking on surgery.

4.6 Pelvic pain and/or dyspareunia

Postoperative vaginal and pelvic pain following POP surgery (native tissue or mesh based) is an extremely difficult and frustrating condition to deal with. If a mesh has been used, the patient may attribute the symptoms to the product. There is also no guarantee that removal of the mesh will alleviate the symptoms. The main risk factor for the development or persistence of postoperative pain is the presence of preoperative pain. The pain may be exacerbated by any intrinsic or extrinsic stimulus. Recovery is delayed and sometimes protracted. Pelvic surgery itself may exacerbate systemic pain. The presence of a graft may be an additional deleterious stimulus.

4.7 Pregnancy

There are no clear data regarding pregnancy in women who have undergone transvaginal mesh repair. Women who have not completed their families should therefore not have a mesh-based prolapse operation.

4.8 Atrophy

Always treat vulvovaginal atrophy adequately before performing a vaginal mesh-based prolapse repair.

4.9 Immunocompromised patients (diabetes mellitus, steroid use, HIV/AIDS)

These women potentially experience poor healing postoperatively because of an impaired or abnormal inflammatory response. This increases the risk for vaginal mesh erosions. Caution should be exercised before considering a prolapse repair with a mesh-based product in these women.

4.10 Smoking

Smoking is associated with an increased risk of mesh erosion, which is likely to be due to reduced vascularity. In one series, the risk for erosion was increased seven-fold in smokers.[11]

4.11 Body mass index (BMI)

Apart from being a risk factor for POP in epidemiological studies, an increased BMI has been associated with an increased risk of
Primary anterior repair of stage 1 and 2 cystoceles should ideally be performed without mesh. Mesh erosion and wound infection. In one series, the risk of erosion increased ten-fold in women with a BMI >30.[12]

4.12 Concurrent hysterectomy
If a vaginal hysterectomy is performed (especially if a T-incision results at the vaginal cuff from an anterior wall incision), the risk of mesh erosion increases significantly.[13]

5. Aspects of informed consent for vaginal mesh
The following aspects need to be addressed in the patient counselling process before informed consent can be given for the use of vaginal mesh products:
- Information on the lack of good-quality evidence and long-term outcomes
- Alternatives to surgical management (e.g. pessaries, pelvic floor exercises)
- Specific potential benefits and complications associated with vaginal mesh products
- Alternatives such as traditional tissue repairs and abdominal sacrocolpopexy (open or endoscopic)
- Complications discussed should include: mesh exposure/erosion, dyspareunia, chronic pelvic pain, vaginal scarring/stricture and fistula formation, and the patient should be told that the removal of the mesh may not resolve pain complications
- Specific information on the type of mesh to be used should be communicated to the patient.

6. Training of pelvic floor surgeons
It is essential that surgeons performing vaginal mesh procedures be adequately trained and possess the required anatomical knowledge, surgical skills and experience for pelvic floor reconstruction. Specific knowledge of a mesh product should be acquired, for different products demand different training and skills.

It is essential that surgical training should be ‘hands-on’ training on multiple occasions. Simple observation of theatre cases is insufficient to demonstrate adequate expertise in performing these surgical procedures.

Before being trained in and performing vaginal mesh procedures, surgeons should be competent in native tissue prolapse repairs such as anterior colporrhaphy, posterior repair, and vaginal suspension procedures (sacrospinous or uterosacral ligament fixation).

7. Accepted indications for different mesh-based products
Before embarking on use of a vaginal mesh-based device, consider the following:
- Abdominal sacrocolpopexy is the gold standard for apical compartment prolapse and should be offered if possible.
- Mesh-based products in the posterior compartment have not been shown to be associated with significantly better outcomes than native tissue repairs.
- Primary anterior repair of stage 1 and 2 cystoceles should ideally be performed without mesh.

Apical suspension and/or vaginal hysterectomy are excellent options in women with mainly uterine prolapse, and mesh is usually not necessary as a first-line treatment.

7.1 Anterior vaginal compartment mesh kits (Anterior Avaulta, Elevate, Nuvia, Perigee, Restorelle DirectFix, Uphold)
The anatomical recurrence rate is lower with mesh (synthetic or biological) compared with anterior colporrhaphy alone. There is no significant difference in quality of life outcomes or de novo dyspareunia with polypropylene mesh; however, with mesh kits there is a higher re-operation rate (mostly due to complications such as erosion).[13] These tend to increase with time after exposure.[14]

Possible indications include:
- Recurrent anterior compartment prolapse with not more than stage 1 apical prolapse (attempt to identify the reason for recurrence to guide individual management plan, though level 1 evidence is lacking)
- Primary stage 3 - 4 cystocele with no more than stage 1 apical prolapse
- Clear evidence of a lateral (paravaginal) defect cystocele.

It is essential to be aware that an advanced-stage cystocele (3 - 4) is mostly associated with an accompanying apical support defect. It is therefore imperative that apical support be provided along with the anterior repair. In the case of mesh kits, this would imply sacrospinous ligament anchoring.

7.2 Posterior vaginal compartment mesh kits (Apogee, Posterior Avaulta, Elevate, Nuvia, and Restorelle DirectFix)
There is no clear evidence supporting the use of vaginal mesh as an alternative for a posterior tissue repair.[15] The addition of mesh does not improve anatomical outcome or quality of life outcome measures, but may give rise to mesh-associated complications.

Possible indications include:
- Recurrent posterior compartment prolapse due to poor tissue quality
- Posterior compartment prolapse > stage 2 with associated apical descent.

7.3 Combined anterior and posterior vaginal mesh
Possible indications include:
- Vault prolapse in women not suitable for abdominal sacrocolpopexy
- In women with uterine prolapse > stage 2, it may be better to perform a vaginal hysterectomy and anterior tissue repair.

8. Final comment
Conservative management and native tissue repairs must be discussed as an alternative prior to using a mesh device. When anatomical evidence dictates otherwise (e.g. information gained with imaging, i.e. levator avulsion), a mesh device may be considered. An abdominal mesh procedure (sacroscopy) is better than a vaginal mesh approach. Complications are increased after
procedures done by low-volume mesh users (surgeons) and formal training is strongly recommended. The ongoing post-marketing studies (FDA 522) should be monitored closely.

The FDA has approved safety guidelines for surgeons who continue to make use of mesh, and SAUGA strongly endorses these.

The American Urogynecologic Society also provides an informed consent toolkit available for public use and patient education.[15]

Most recently an International Urogynecological Association round table submitted recommendations on the appropriateness of the use of mesh in vaginal surgery.[14] For additional resources and membership information, visit www.sauga.org.za

Authorship and process followed. This statement was prepared by Dr E W Henn on behalf of the South African Urogynaecology Association (SAUGA). It was reviewed by the Executive on 28 January 2014, after which this final statement was agreed upon. SAUGA Executive: Drs S T Jeffery, Z Abdool, J C Coetzee, H S Cronje, P de Jongh, E W Henn, B Moser, S Ramphal, P Swart, J R van Rensburg, F van Wijk.